Editas Medicine (EDIT) PT Raised to $40 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.72 +4.62%
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
BMO Capital analyst George Farmer raised the price target on Editas Medicine (NASDAQ: EDIT) to $40.00 (from $28.00) while maintaining a Outperform rating.
- $225K/year price tag of newly FDA-approved Vyndaquel and Vyndamax (tafamidis; Pfizer) for treatment ATTR-cardiomyopathy (ATTR-CM).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zimmer Biomet (ZBH) PT Raised to $125 at Stifel
- Pfizer (PFE) PT Raised to $40 at Argus
- GXO Logistics Inc. (GXO) PT Raised to $72 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO Capital, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
